AVROBIO
One Kendall Square
Building 300, Suite 201
Cambridge
MA
02139
United States
Tel: 617.914.8420
Website: https://avrobio.com/
Email: info@AVROBIO.com
About AVROBIO
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR RD 01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases.
We are headquartered in Cambridge, MA and have offices in Toronto, ON. Please visit our website www.avrobio.com for more information on who we are, what we care about and how we are bringing these therapies to our patients.
160 articles about AVROBIO
-
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
10/26/2021
AVROBIO, Inc. today announced the appointment of Essra Ridha, M.D., MRCP, FFPM, as chief medical officer.
-
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
10/19/2021
AVROBIO, Inc. today reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of action of its gene therapies.
-
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
10/6/2021
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
-
AVROBIO Announced Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/5/2021
AVROBIO, Inc. today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 201,750 shares of the company’s common stock to eight new employees as inducement awards under the company’s 2019 Inducement Plan.
-
With multiple job openings across the industry, biotech and biopharma employers have to come up with different strategies to retain top talent.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2021
9/3/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 83,750 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO to Participate at Four Upcoming Investor Conferences
9/1/2021
AVROBIO, Inc. today announced that members of its senior management team are scheduled to participate in four upcoming virtual investor conferences.
-
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
8/5/2021
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2021
8/4/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 75,500 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO to Present at Two Upcoming Investor Conferences in August 2021
8/2/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that members of its senior management team are scheduled to participate in two upcoming investor conferences:
-
AVROBIO to Present at the JMP Securities Life Sciences Conference
6/10/2021
AVROBIO, Inc. today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Thursday, June 17, 2021.
-
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021
6/4/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan.
-
AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update
5/13/2021
Held meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01 for Fabry disease Dosing completion in ongoing FAB-GT Phase 2 trial reaches 50%, with three additional patients dosed in three months
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2021
5/6/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 163,500 shares of the company’s common stock to five new employees as inducement awards, consisting of 30,500 shares granted under the company’s 2019 Inducement Plan and 133,000 shares granted under the company’s 2020 Inducement Plan.
-
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
5/3/2021
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; plan to enroll a total of up to 14 participants
-
AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting
4/27/2021
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of lysosomal disorder gene therapy programs will be shared at the 24th virtual Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), May 11-14, 2021.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2021
4/6/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 140,000 shares of the company’s common stock to 10 new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
3/18/2021
100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato ® gene therapy platform in FAB-GT 1 trial for Fabry disease One new patient dosed and three new patients enrolled in Fabry disease clinical trial since January 2021 Orphan drug designation received from European Commission for AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 05, 2021
3/5/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 61,500 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis
3/1/2021
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis.